logo

Emergent Biosolutions Inc (EBS)



Trade EBS now with
  Date
  Headline
10/10/2019 6:56:43 AM Emergent BioSolutions Receives EMA Prime Designation For Chikungunya Virus VLP Vaccine Candidate
9/27/2019 6:42:11 AM Emergent BioSolutions Receives NIH Research Grant To Further Develop AP007 For Addiction In Opioid Use Disorder
6/3/2019 6:43:45 AM Emergent BioSolutions Awarded 10-Yr HHS Contract Valued At About $535 Mln To Deliver VIGIV
6/3/2019 6:39:20 AM Emergent BioSolutions Secures 10-Yr HHS Contract Valued At $535 Mln
4/16/2019 6:34:45 AM Emergent BioSolutions Announces Interim Results From Phase 2 Study Of CHIKV-VLP, Chikungunya Virus Vaccine Candidate
3/19/2019 6:37:45 AM Emergent BioSolutions Begins Phase 3 Clinical Study To Evaluate AV7909
2/12/2019 6:37:16 AM Emergent BioSolutions Appoints Seamus Mulligan To Board
1/24/2019 7:07:12 AM Emergent BioSolutions Appoints Robert Kramer To Board
1/7/2019 6:37:28 AM Emergent BioSolutions Anticipates 2018 Total Revenue Of $779 Mln-$784 Mln
1/4/2019 7:02:52 AM Emergent BioSolutions: Daniel Abdun-Nabi To Retire As CEO; Robert Kramer To Become President And CEO
12/28/2018 9:19:30 AM Emergent BioSolutions Announces Submission To FDA Of Application Covering Emergency Use Authorization For NuThrax
8/16/2018 6:16:34 AM CEPI Awards Contract Worth Up To $36 Mln To Profectus BioSciences, Emergent BioSolutions To Develop Lassa Virus Vaccine
8/9/2018 6:38:58 AM Emergent BioSolutions To Acquire PaxVax From Cerberus Capital Management; Transaction To Close In Q4
8/9/2018 6:37:00 AM Emergent BioSolutions To Acquire PaxVax For All-cash Consideration Of $270 Mln
8/2/2018 4:37:07 PM Emergent BioSolutions Q2 EPS $0.98 Vs. $0.11 Year Ago
6/7/2018 6:30:40 AM Emergent BioSolutions Announces $50 Mln Expansion To Camden Fill/finish Facility
5/24/2018 6:12:06 AM CEPI Awards $25 Mln Contract To Profectus BioSciences And Emergent BioSolutions To Develop Nipah Virus Vaccine
  
 
>